Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

With a market cap of $145.7 billion, Pfizer Inc. (PFE) is a global, research-driven biopharmaceutical company, specializing ...

PFE’s Stock Performance, Rising Estimates & Attractive Valuation. Pfizer’s stock has declined 6.9% in the past year compared with a decrease of 1.6% for the industry.

We upgraded the rating for Pfizer (PFE) stock, ... I don't think Pfizer performance improvement is adequate when comparing against SP500. Reply. Like. Robert Hutten. 28 Aug. 2024.

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products. With a market cap of $149.8 billion, the company offers ...

Pfizer Inc. closed 18.77% short of its 52-week high of $31.54, which the company achieved on July 30th.

Pfizer and S&P 500 Performance During 2007-08 Crisis. PFE stock declined from nearly $12 in September 2007 (pre-crisis peak) to $7 in March 2009 (as the markets bottomed out), implying it lost 45% ...

Pfizer (PFE-1.29%) is a stock that everyone's familiar with, ... So while bulls might be disappointed with its stock price performance, ...

PFE stock has seen a decline of 15% from levels of $35 in early January 2021 to around $30 now, vs. an increase of about 15% for the S&P 500 over this roughly 3-year period. However, the decrease ...

Pfizer’s PFE fourth-quarter results were strong as it beat estimates for earnings as well as sales. Adjusted earnings per share of 63 cents were much higher than 10 cents in the year-ago quarter ...